Skip to main content

Charles River Laboratories company profile

  • CRL · NYSE
  • Biotechnology
  • Life Sciences Tools & Services
  • S&P 500
$335.52−0.72%Close 16 Nov 2026 · Market value $16.05B

About Charles River Laboratories

Charles River Laboratories provides non-clinical drug development services, research models, and quality control products for manufacturing. Its Research Models and Services (RMS) segment produces and sells purpose-bred rodents and other research models, and offers research model services, including Insourcing Solutions, genetically engineered model services, research animal diagnostics, and human donor-derived cell materials. Its Discovery and Safety Assessment (DSA) segment provides outsourced discovery, toxicology, pathology, safety pharmacology, and bioanalysis services. Its Manufacturing segment provides microbial quality control testing, biologics testing, and contract development and manufacturing for cell and gene therapies. Customers include pharmaceutical and biotechnology companies, contract research and manufacturing organizations, hospitals, academic institutions, and government agencies. The company operates over 120 sites in more than 20 countries.

A summary of the business section of the company's latest annual report, filed 18 Feb 2026.

Company facts

TickerCRL · NYSE
SectorBiotechnology
IndustryLife Sciences Tools & Services
IndexS&P 500
Fiscal year ends27 December
Reporting currencyUSD
CIK1100682
Latest annual report10-K, filed 18 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
James C. FosterDirector361K · < 1%Option exercise, 22 Oct 2026
Birgit GirshickChief Executive Officer · Director76.3K · < 1%Gift, 19 Aug 2026
Victoria CreamerEVP & Chief People Officer30.8K · < 1%Open-market sale, 6 Aug 2026
Joseph W. LaPlumeEVP, Corp Strategy & Develop28.2K · < 1%Gift, 10 Aug 2026
Martin MackayDirector24.6K · < 1%Grant or award, 8 May 2026
Virginia M. WilsonDirector15.2K · < 1%Grant or award, 8 May 2026
Nancy C. AndrewsDirector14.9K · < 1%Option exercise, 18 Aug 2026
George Llado, Sr.Director13.6K · < 1%Grant or award, 8 May 2026
Michael KnellSVP, Finance and CAO11.5K · < 1%Shares withheld for tax, 6 Nov 2026
Craig ThompsonDirector8.1K · < 1%Grant or award, 8 May 2026
Flavia H. PeaseCorporate Executive VP & CFO7.0K · < 1%Shares withheld for tax, 31 May 2025
Reshema Kemps-PolancoDirector6.4K · < 1%Grant or award, 8 May 2026
Steven BargDirector3.5K · < 1%Grant or award, 2 Jun 2026
Abraham CeesayDirector3.0K · < 1%Grant or award, 8 May 2026
Mark EnyedyDirector3.0K · < 1%Grant or award, 8 May 2026
Paul GravesDirector3.0K · < 1%Grant or award, 8 May 2026
Parisotto Shannon MCEVP, Disc &amp; Safety Assessment—Option exercise, 21 Oct 2026
Coleman GlennEVP &amp; Chief Financial Officer—Open-market purchase, 30 Sep 2026
Mintz MarkEVP, Chief Information Officer—Shares withheld for tax, 31 May 2026
MASSARO GEORGEDirector—Sale under a 10b5-1 plan, 15 May 2025

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

CRL in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.